

Vivian P Bykerk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2978831/publications.pdf>

Version: 2024-02-01

136
papers

21,801
citations

76031

42
h-index

18944

123
g-index

142
all docs

142
docs citations

142
times ranked

20649
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
4	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
5	Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. <i>Nature</i> , 2017, 542, 110-114.	13.7	767
6	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019, 20, 928-942.	7.0	760
7	Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. <i>Nature Communications</i> , 2018, 9, 789.	5.8	368
8	Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. <i>Arthritis and Rheumatism</i> , 1994, 37, 32-40.	6.7	325
9	Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. <i>Nature Communications</i> , 2018, 9, 791.	5.8	284
10	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
11	Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2012, 39, 1559-1582.	1.0	250
12	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
13	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 19-26.	0.5	201
14	Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and <i>scRNA</i> Sequencing Data. <i>Arthritis and Rheumatology</i> , 2018, 70, 690-701.	2.9	157
15	Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1993, 36, 795-803.	6.7	152
16	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
17	Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 681-686.	0.5	150
18	HBEFG ⁺ macrophages in rheumatoid arthritis induce fibroblast invasiveness. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	143

#	ARTICLE	IF	CITATIONS
19	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.5	131
20	Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety. <i>Journal of Rheumatology</i> , 2012, 39, 1583-1602.	1.0	122
21	Mixed-effects association of single cells identifies an expanded effector CD4 ⁺ T cell subset in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	119
22	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
23	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
24	A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 13-22.	0.5	95
25	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018, 20, 139.	1.6	93
26	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1950-1954.	0.5	91
27	Sustained rheumatoid arthritis remission is uncommon in clinical practice. <i>Arthritis Research and Therapy</i> , 2012, 14, R68.	1.6	83
28	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 1997-2009.	1.0	78
29	Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 740-747.	0.5	73
30	Serum 14-3-3 $\hat{\imath}$ is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	1.0	72
31	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. <i>Rheumatology</i> , 2012, 51, 1416-1425.	0.9	71
32	Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2361-2369.	1.0	71
33	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	1.4	68
34	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. <i>Journal of Rheumatology</i> , 2014, 41, 799-809.	1.0	65
35	Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1352-1354.	0.5	65
36	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.5	63

#	ARTICLE	IF	CITATIONS
37	Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. <i>Rheumatology</i> , 2016, 55, 1959-1968.	0.9	59
38	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1003-1008.	0.5	56
39	Delay in receiving rheumatology care leads to long-term harm. <i>Arthritis and Rheumatism</i> , 2010, 62, 3519-3521.	6.7	54
40	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016, 2, e000225.	1.8	54
41	Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry. <i>Journal of Rheumatology</i> , 2014, 41, 227-234.	1.0	52
42	The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity. <i>Journal of Rheumatology</i> , 2012, 39, 2071-2080.	1.0	46
43	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019, 5, e000942.	1.8	45
44	Earlier Time to Remission Predicts Sustained Clinical Remission in Early Rheumatoid Arthritis – Results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014, 41, 2161-2166.	1.0	44
45	The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. <i>Rheumatology</i> , 2012, 51, vi16-vi20.	0.9	43
46	Early rheumatoid arthritis: The performance of the 2010 ACR/EULAR criteria for diagnosing RA. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 451-466.	1.4	43
47	Management of perioperative tumour necrosis factor inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. <i>Rheumatology</i> , 2016, 55, kev364.	0.9	41
48	Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors. <i>Journal of Rheumatology</i> , 2018, 45, 604-611.	1.0	41
49	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. <i>Journal of Rheumatology</i> , 2015, 42, 2185-2189.	1.0	40
50	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1185-1191.	1.5	38
51	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. <i>Rheumatology</i> , 2014, 53, 1075-1086.	0.9	37
52	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2015, 34, 563-571.	1.0	36
53	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
54	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192.	2.9	35

#	ARTICLE	IF	CITATIONS
55	Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1422-1430.	1.0	34
56	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 14.	0.9	33
57	Remission in Early Rheumatoid Arthritis – A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. <i>Journal of Rheumatology</i> , 2012, 39, 1155-1158.	1.0	32
58	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015, 10, e0135327.	1.1	32
59	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
60	Development of a self-administered early inflammatory arthritis detection tool. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 50.	0.8	31
61	Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils. <i>Arthritis and Rheumatology</i> , 2020, 72, 557-564.	2.9	30
62	Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 272-8.	0.4	30
63	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. <i>Rheumatology</i> , 2016, 55, 1751-1762.	0.9	29
64	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
65	14-3-3 β Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1587-1594.	1.0	28
66	Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1823-1830.	1.0	26
67	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017, 12, e0189840.	1.1	26
68	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	1.0	25
69	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. <i>Rheumatology International</i> , 2013, 33, 1105-1120.	1.5	23
70	Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 46-54.	1.0	23
71	Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2019, 71, 1034-1041.	2.9	19
72	The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. <i>Rheumatology</i> , 2017, 56, kew474.	0.9	18

#	ARTICLE	IF	CITATIONS
73	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1501-1505.	0.5	17
74	Identifying Minimal and Meaningful Change in a <sc>Patient-Reported</sc> Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. <i>Arthritis Care and Research</i> , 2022, 74, 588-597.	1.5	17
75	Adding a "GRADE" to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 1274-1285.	2.4	16
76	HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. <i>Arthritis Research and Therapy</i> , 2021, 23, 245.	1.6	16
77	The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic?. <i>Rheumatology</i> , 2012, 51, vi10-vi15.	0.9	15
78	Reduction in Serum Uric Acid may be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S38092.	0.3	15
79	Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 1245-1250.	1.5	15
80	Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2022, 41, 1619-1622.	1.0	15
81	Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 595-604.	0.9	13
82	Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking. <i>Rheumatology</i> , 2021, 60, 4306-4314.	0.9	13
83	Achieving remission in clinical practice: lessons from clinical trial data. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 621-32.	0.4	13
84	Validation of a Self-administered Inflammatory Arthritis Detection Tool for Rheumatology Triage. <i>Journal of Rheumatology</i> , 2013, 40, 417-424.	1.0	12
85	Pragmatism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 620-628.	1.5	12
86	What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life. <i>Arthritis Care and Research</i> , 2020, 72, 1571-1578.	1.5	12
87	<p>Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study</p><p>Patient Preference and Adherence, 2020, Volume 14, 829-838.	0.8	12
88	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
89	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
90	Patient-Reported Outcomes Measurement Information System Versus Legacy Instruments. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 211-229.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 1104-1111.	1.5	10
92	Strategies to prevent rheumatoid arthritis in high-risk patients. <i>Current Opinion in Rheumatology</i> , 2011, 23, 179-184.	2.0	10
93	Detecting the Earliest Signs of Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 669-683.	0.8	9
94	Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study. <i>Rheumatology</i> , 2022, 61, 606-616.	0.9	9
95	Evaluating Quality of Care for Rheumatoid Arthritis for the Population of Alberta Using System-level Performance Measures. <i>Journal of Rheumatology</i> , 2021, 48, 482-485.	1.0	9
96	2011 remission criteria are a new benchmark for RA therapy. <i>Nature Reviews Rheumatology</i> , 2011, 7, 317-318.	3.5	8
97	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. <i>RMD Open</i> , 2019, 5, e000840.	1.8	8
98	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. <i>Journal of Rheumatology</i> , 2019, 46, 1168-1172.	1.0	8
99	The efficacy and safety of targeting GM-CSF in arthritis. <i>Lancet Rheumatology, The</i> , 2020, 2, e648-e650.	2.2	8
100	A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2022, 4, 57-64.	0.9	8
101	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. <i>BMC Health Services Research</i> , 2019, 19, 572.	0.9	7
102	Treatment strategies for early rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 375-383.	2.0	6
103	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1406-1408.	1.0	6
104	Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination. <i>Lancet Rheumatology, The</i> , 2022, 4, e85-e87.	2.2	6
105	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019, 1, 471-479.	0.9	5
106	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. <i>Journal of Rheumatology</i> , 2020, 47, 333-340.	1.0	5
107	Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months. <i>Arthritis Care and Research</i> , 2022, 74, 131-141.	1.5	5
108	Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. <i>Journal of Rheumatology</i> , 2022, 49, 998-1005.	1.0	5

#	ARTICLE	IF	CITATIONS
109	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 2225-2231.	1.5	4
110	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
111	Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. <i>ACR Open Rheumatology</i> , 2021, 3, 501-511.	0.9	4
112	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	0.9	4
113	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 737-741.	1.5	3
114	LB0008...THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY OF ABATACEPT AND ADALIMUMAB IN SEROPOSITIVE BIOLOGIC-NAÏVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA: DATA FROM A HEAD-TO-HEAD SINGLE-BLINDED TRIAL. , 2019, , .		3
115	A Call to Systematically Monitor for Adverse Events in Users of Low-Dose Methotrexate Therapy. <i>Annals of Internal Medicine</i> , 2020, 172, 425.	2.0	3
116	Preclinical Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xv-xviii.	0.8	2
117	OP0315...ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS. , 2019, , .		2
118	1201...Flares after SARS-Cov-2 vaccination in patients with systemic lupus erythematosus. , 2021, , .		2
119	Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017-2021: Results From the Canadian Early Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2022, 4, 566-573.	0.9	2
120	Radiographic Progression in Rheumatoid Arthritis: Does It Still Happen and Does It Matter?. <i>Journal of Rheumatology</i> , 2014, 41, 2337-2339.	1.0	1
121	Low-dose Glucocorticoid Use Does Not Reduce Biologic Use in Early RA, Nor Do Biologics Reduce the Need for Glucocorticoids. <i>Journal of Rheumatology</i> , 2019, 46, 331-332.	1.0	1
122	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. <i>RMD Open</i> , 2019, 5, e000931.	1.8	1
123	EP25...Impact of sarilumab on unacceptable pain and inflammation control in moderately-to-severely active rheumatoid arthritis (RA) patients in 3 Phase 3 studies. <i>Rheumatology</i> , 2020, 59, .	0.9	1
124	Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts. <i>Journal of Rheumatology</i> , 2022, 49, 16-25.	1.0	1
125	O87...On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	0.9	1
126	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 449.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Moving towards IMPROVED drug-free remission. Nature Reviews Rheumatology, 2018, 14, 191-192.	3.5	0
128	THU0153â€¦PATTERNS OF SUSTAINED REMISSION AND SUBSEQUENT DMARD TAPERING IN EARLY RHEUMATOID ARTHRITIS: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .		0
129	OP0089â€¦METABOLIC SYNDROME IS COMMON AROUND THE TIME OF EARLY RHEUMATOID ARTHRITIS DIAGNOSIS AND ASSOCIATIONS VARY BY SEX AND MENOPAUSAL STATUS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .		0
130	AB1079â€¦CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS: PHENOTYPES AND CYTOKINE ASSOCIATIONS. , 2019, , .		0
131	FR10065â€¦PATIENT-REPORTED PALINDROMIC SYMPTOMS IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .		0
132	AB1304â€¦THE RHEUMATOID ARTHRITIS FLARE QUESTIONNAIRE (RA-FQ) IS AN EASY TO ADMINISTER PATIENT-REPORTED OUTCOME MEASURE THAT TRACKS WELL WITH THE CLINICAL DISEASE ACTIVITY INDEX (CDAI) OVER TIME IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (ERA) IN 2 DIFFERENT HEALTH SETTINGS. , 2019, , .		0
133	OP0269â€¦HPR PATTERNS OF FATIGUE AND PREDICTORS OF SIGNIFICANT IMPROVEMENT IN THE 1ST YEAR OF RA: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). , 2019, , .		0
134	Reply. Arthritis and Rheumatology, 2021, 73, 175-176.	2.9	0
135	Reply. Arthritis and Rheumatology, 2021, 73, 357-358.	2.9	0
136	Modification of immunomodulatory medications by rheumatology patients during the peak of the COVID-19 pandemic in New York City. Clinical Rheumatology, 0, , .	1.0	0